The interest in minimally invasive glaucoma surgical (MIGS) procedures and devices stems from a desire to have a surgical option for the treatment of glaucoma that is associated with less serious risks and fewer complications than established procedures. Furthermore, a relatively simple and safe surgical approach may help to reduce side effects associated with medication use and to reduce the problem of poor adherence with medical therapy in glaucoma patients. The Food and Drug Administration (FDA) Center for Devices and Radiological Health has received many requests for investigational trials for novel glaucoma surgical devices. Still, there is no consensus regarding the appropriate populations in which to implant these devices, nor are there uniform views by ophthalmologists and researchers concerning the best methods for the assessment of their safety and effectiveness. The FDA and the American Glaucoma Society collaborated in hosting a public meeting on February 26, 2014, in Washington, DC, to discuss guidelines for the evaluation of the safety and effectiveness of MIGS devices. Glaucoma specialists from across the United States and Canada discussed the appropriate clinical trial populations and defined clear and reasonable outcomes for the evaluation of their safety and effectiveness.